This Week In Medicine

This Week In Medicine

Download on the App Store

This Week In Medicine episodes

  • N Engl J Med 2026;394:51-61 Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

    patients suffering from a particularly aggressive form of cancer known as true extramedullary myeloma. By simultaneously attacking two different markers on cancer cells using the drugs talquetamab and teclistamab, researchers achieved a high overall response rate in a population that usually faces very poor odds. While the treatment proved effective at shrinking tumors and extending survival, it also carried a high incidence of severe adverse events, specifically regarding infections and hematologic issues. Ultimately, the research suggests that this dual-targeting approachoffers a powerful new strategy for managing drug-resistant disease, provided that the significant safety risks are carefully managed.

    15 min
  • NEJM: Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

    This clinical study investigates whether combining the targeted drug osimertinib with traditional chemotherapy offers a superior outcome for patients facing a specific type of advanced lung cancer. By comparing this dual approach against the standard single-drug therapy, researchers discovered that the combination treatment significantly extended the livesof participants by nearly ten months. While the combined regimen proved more effective at keeping the disease at bay, it also resulted in a higher frequency of severe side effects compared to the solo medication. Ultimately, the trial demonstrates a clear survival advantage for this aggressive frontline strategy, providing a more potent but more intensive option for managing this complex malignancy.

    11 min
  • N Engl J Med 2026;394:13-26 Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC

    This study evaluates the effectiveness of sacituzumab tirumotecan, a novel antibody-drug conjugate, for patients with advanced lung cancer whose disease has worsened despite standard treatments. By comparing this new drug against traditional chemotherapy, researchers discovered that it doubled the duration of progression-free survival and significantly extended the lives of those involved in the trial. While side effects like low white blood cell counts were observed, the therapy demonstrated a superior clinical benefit and a manageable safety profile compared to the existing standard of care. Ultimately, the results suggest that this targeted approach offers a transformative secondary treatment option for patients facing resistant forms of EGFR-mutated cancer.

    10 min
  • Most Popular Articles JAMA 2025 Episode 2:Screening for Osteoporosis to Prevent Fractures US Preventive Services Task Force Recommendation Statement

    This clinical guideline establishes a framework for using medical screenings to identify bone density loss before it leads to debilitating injuries. The document highlights that osteoporotic fractures are severe events that can strip individuals of their independence or even lead to mortality. Based on a rigorous evidence assessment, the task force issues a formal recommendation for all women aged 65 and older, as well as younger postmenopausal women with specific risk factors, to undergo testing. Conversely, the text notes that there is currently insufficient evidence to determine if the benefits of routine screening outweigh the potential harms for the male population. Overall, the text serves as a strategic roadmap for preventative care, aiming to reduce the physical and psychological toll of bone fragility through timely intervention.

    11 min
  • Most Popular Articles JAMA 2025 Episode 1:The DECAF Trial

    The DECAF Trial challenged the long-held medical assumption that caffeine triggers irregular heart rhythms by investigating its actual impact on patients with atrial fibrillation. Researchers conducted a randomized experiment where one group continued drinking caffeinated coffee while the other practiced complete abstinence following a heart procedure. Surprisingly, the data revealed that those who consumed at least one cup of coffee daily experienced a significantly lower rate of arrhythmia recurrencecompared to those who avoided it. Ultimately, the study suggests that moderate coffee consumption may actually provide a protective benefit for heart rhythm stability rather than acting as a harmful stimulant.

    13 min
  • The Lancet December 2025:Neurobehavioural links from infant screen time to anxiety

    This research explores how early exposure to digital media impacts the long-term mental health of children by tracing a specific neurodevelopmental pathway from infancy to adolescence. By monitoring brain growth over several years, scientists discovered that excessive screen time during the first two years of life leads to an accelerated maturation of brain networks responsible for vision and cognitive control. This premature structural change eventually manifests as impaired decision-making speeds, which serves as a critical bridge to increased anxiety symptoms by age thirteen. Ultimately, the study reveals that the sensory overstimulation provided by screens may disrupt healthy brain integration, offering a new biological explanation for why limiting early childhood screen use is vital for emotional stability later in life.

    14 min
  • Best of JAMA 2025: Episode 9:Nicotinamide for Skin Cancer Chemoprevention

    This extensive medical study investigates whether taking nicotinamide, a form of vitamin B3, can effectively serve as a preventative measure against skin cancer for both the general public and high-risk transplant patients. By analyzing health records from over 30,000 veterans, researchers discovered that a daily supplement significantly lowered the overall risk of developing further malignancies, particularly squamous cell carcinoma. The data suggests that the treatment is most powerful when started immediately after a first diagnosis, as the protective benefits appear to diminish if the intervention is delayed until after multiple cancers have occurred. Ultimately, the findings highlight nicotinamide as a promising tool for long-term skin protection, though its effectiveness varies depending on a patient's specific medical history.Å

    12 min
  • Best of JAMA 2025: Episode 8:Association of Endothelial Dysfunction With Chronic Marijuana Smoking and THC-Edible Use

    The CANDIDE study investigated the impact of long-term cannabis use on cardiovascular health by comparing non-users to those who frequently smoke marijuana or consume THC-infused edibles. By measuring how well blood vessels dilate and testing cell reactions to user serum, researchers discovered that both forms of consumption lead to significant endothelial dysfunction, a condition where the lining of the blood vessels fails to function properly. Interestingly, while the physical impairment of the arteries was similar to that caused by tobacco, the underlying biological mechanisms appeared to differ depending on whether the THC was inhaled or ingested. Ultimately, the findings suggest that frequent cannabis use, regardless of the delivery method, may pose a substantial risk to vascular integrity that correlates directly with the frequency and dosage of use.

    14 min
  • Best of JAMA 2025: Episode 7: Global Estimates of Lives and Life-Years Saved by COVID-19 Vaccination During 2020-2024

    This research provides a comprehensive assessment of the global public health impact of COVID-19 immunizations from 2020 through late 2024. By analyzing diverse demographics and viral waves, the study concludes that vaccines prevented millions of deaths and preserved nearly 15 million life-years, though these benefits were not distributed equally across all age groups. The data reveals that the vast majority of lives saved belonged to individuals aged 60 and older, while the impact on children and young adults was statistically minimal. Ultimately, the authors use these conservative estimates to demonstrate that while the primary protection was concentrated among the elderly, the overall effort resulted in a profound preservation of human life on a global scale.

    16 min
  • Best of JAMA 2025: Episode 6:Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration

    This research study investigates a potential link between popular metabolic medications and a serious vision-threatening condition known as neovascular age-related macular degeneration. By analyzing a massive database of elderly patients with diabetes, scientists discovered that those who used GLP-1 receptor agonists for at least six months faced double the risk of developing this specific eye disease compared to those not taking the drugs. The findings highlight a critical need for clinicians to weigh the systemic benefits of these treatments against possible long-term ocular complications. Ultimately, the study calls for deeper investigation into the biological reasons behind this association to ensure the safe management of patients on long-term therapy.

    14 min

About This Week In Medicine

From the publisher's feed

Welcome to This Week in Medicine - Your Filtered Medical Journal SummaryLooking to stay up-to-date with the latest medical research but short on time? This Week in Medicine has you covered!Our AI…